MBL77 - AN OVERVIEW

mutations provided The point that, as described below, CLL therapy is based on the presence or absence of those mutations. The existing consensus is the fact, other than clonal mutations, subclonal mutations having a variant allelic frequency starting from five to 10% (and for that reason beneath the brink of detection by conventional molecular tac